NCT03234712: A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for dose expansion phase
Exclusions: Patients with symptomatic uncontrolled metastases from an extracranial solid tumor to the central nervous system (CNS)- see trial for details; Patients who have had more than 3 lines of systemic cytotoxic therapy (excluding adjuvant and neoadjuvant therapy)

Comments are closed.

Up ↑